Abstract | PURPOSE: EXPERIMENTAL DESIGN:
Pralatrexate was administered i.v. every 2 weeks (days 1 and 15) in a 4-week cycle. Depending on the taxane used and dose being tested, the taxane was administered on days 1 and 15; days 2 and 16; or days 1, 8, and 15. In the latter part of the study, patients in the docetaxel arm were treated with vitamin B(12) and folic acid supplementation to mitigate toxicity and allow pralatrexate dose escalation. RESULTS: CONCLUSIONS:
|
Authors | Christopher G Azzoli, Lee M Krug, Jorge Gomez, Vincent A Miller, Mark G Kris, Michelle S Ginsberg, Roxanne Henry, Jessica Jones, Leslie Tyson, Megan Dunne, Barbara Pizzo, Amy Farmer, Ennapadam Venkatraman, Robert Steffen, F M Sirotnak |
Journal | Clinical cancer research : an official journal of the American Association for Cancer Research
(Clin Cancer Res)
Vol. 13
Issue 9
Pg. 2692-8
(May 01 2007)
ISSN: 1078-0432 [Print] United States |
PMID | 17473201
(Publication Type: Clinical Trial, Phase I, Journal Article)
|
Chemical References |
- 10-propargyl-10-deazaaminopterin
- Folic Acid Antagonists
- Taxoids
- Vitamins
- Homocysteine
- Docetaxel
- Methylmalonic Acid
- Aminopterin
- Paclitaxel
|
Topics |
- Adult
- Aged
- Aminopterin
(administration & dosage, adverse effects, analogs & derivatives)
- Antineoplastic Combined Chemotherapy Protocols
(administration & dosage, adverse effects)
- Dietary Supplements
- Docetaxel
- Female
- Folic Acid Antagonists
(administration & dosage, adverse effects)
- Homocysteine
(blood)
- Humans
- Male
- Methylmalonic Acid
(blood)
- Middle Aged
- Neoplasms
(drug therapy)
- Paclitaxel
(administration & dosage, adverse effects)
- Taxoids
(administration & dosage, adverse effects)
- Vitamins
(administration & dosage)
|